查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1938925

產前DNA定序市場－全球產業規模、佔有率、趨勢、機會及預測（按類型、應用、最終用戶、地區和競爭格局分類，2021-2031年）

Prenatal DNA Sequencing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application, By End user, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球產前DNA定序市場預計將從2025年的26.1億美元成長到2031年的38.9億美元，複合年成長率為6.88%。

該市場專注於分析母體血液中存在的胎兒遺傳物質，以檢測染色體異常和某些遺傳疾病。這主要是由於臨床上越來越傾向於選擇非侵入性檢測而非羊膜穿刺等高風險檢測，以及隨著孕婦年齡成長，對準確評估的需求也效用增加。國際產前診斷學會報告稱，到2024年，在隨機選擇的、經超音波檢查發現異常的妊娠病例中，產前外EXOME定序的診斷率將達到31%，這凸顯了推動這一需求的臨床實用性。

市場概覽
預測期 2027-2031
市場規模：2025年 26.1億美元
市場規模：2031年 38.9億美元
複合年成長率：2026-2031年 6.88%
成長最快的細分市場 遺傳性疾病
最大的市場 北美洲

然而，由於先進定序檢測高成本且報銷政策不統一，市場面臨許多障礙。許多醫療系統和保險公司僅對高風險懷孕提供全額報銷，這造成了經濟障礙，限制了普通低風險族群使用這些基因組技術。這種經濟摩擦阻礙了市場擴張，也使得所有孕婦，無論其風險狀況如何，都無法普遍獲得這些先進的診斷工具。

市場促進因素

隨著醫療機構和孕婦優先選擇更安全、更準確的篩檢方式以避免羊膜穿刺術帶來的流產風險，從傳統侵入性方法向非侵入性產前檢測 (NIPT) 的快速轉變正在推動市場顯著成長。檢測量的顯著成長印證了這一趨勢；例如，Natera 在其 2025 年第一季財報中宣布，該公司已完成約 855,100 例檢測，較去年同期成長 16.2%，凸顯了 NIPT 正在成為主流診療標準。

次世代定序(NGS) 和生物資訊學領域的技術突破正在進一步加速這一成長。諸如單分子計數等創新技術使得更早期、更全面的胎兒評估成為可能。 2025 年 5 月，Myriad Genetics 宣布其產前檢測收入年增 11%，部分原因是其「Prequel 早期妊娠年齡」檢測的推出。此外，BillionToOne 於 2025 年 11 月進行的首次股票公開發行(IPO) 籌集了約 2.73 億美元，進一步證實了該行業強勁的投資吸引力。

市場挑戰

全球產前DNA定序市場成長的主要障礙是先進定定序檢測的高昂費用以及不均衡的報銷政策。儘管臨床上擴大採用無創技術，但高昂的價格使其難以成為低風險族群的標準治療方案。支付方往往認為這些評估僅在高風險妊娠中才具有醫學必要性，導致患者自付費用顯著增加，並限制了檢測量和收入潛力。

這些嚴重的健保覆蓋缺口極大地限制了潛在市場。例如，根據產前篩檢普及聯盟2024年3月發布的報告，美國有四個州的醫療篩檢計劃不為任何孕婦提供非侵入性產前篩檢，無論其風險如何。這些零散的政策迫使基因組學公司在有限的市場範圍內運營，直接阻礙了其規模化發展，並導致其普及率停滯不前。

市場趨勢

市場的一個根本性轉變是非侵入性產前檢測 (NIPT) 的應用範圍從標準的染色體異常篩檢擴展到包括微缺失和單基因疾病，可以直接從母體血液中檢測出囊腫纖維化等疾病。 BillionToOne 公司在 2025 年 1 月發布的一份報告中強調了對這種全面、無風險評估的需求，該報告預測，該公司 2024 年的收入將達到 1.53 億美元，主要得益於其單基因產前檢測業務，該業務預計將佔據美國市場 15% 的佔有率。

同時，第三代長讀長定序技術的應用使得短讀長定序技術難以檢測到的結構突變和重複序列擴增成為可能，從而提高了超音波檢查發現異常懷孕的診斷準確率。為了佐證這一趨勢，牛津奈米孔技術公司於2025年9月發布報告稱，其臨床市場部門上半年的收入成長了52.9%，顯示基於奈米孔的定序技術在臨床診斷中的效用正在迅速擴展。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球產前DNA定序市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按類型（遺傳性疾病、非遺傳性疾病）
    • 依應用領域（血友病、唐氏症、囊腫纖維化、自閉症等）
    • 依最終用戶（醫院/診所、製藥/生技公司、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美產前DNA定序市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲產前DNA定序市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區產前DNA定序市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲產前DNA定序市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美洲產前DNA定序市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球產前DNA定序市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Agilent Technologies Inc
  • BGI Group
  • F. Hoffmann-La Roche ltd
  • Illumina Inc
  • Laboratory Corporation of America Holdings
  • Natera Inc
  • Genomic Health Inc
  • Myriad Genetics Inc
  • PerkinElmer Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 19857

The Global Prenatal DNA Sequencing Market is projected to expand from USD 2.61 Billion in 2025 to USD 3.89 Billion by 2031, reflecting a compound annual growth rate of 6.88%. This market focuses on analyzing fetal genetic material found in maternal blood to detect chromosomal aneuploidies and specific genetic disorders, driven by a growing clinical preference for non-invasive testing over riskier procedures like amniocentesis and the need for accurate evaluations due to rising maternal ages. Highlighting the clinical utility fueling this demand, the International Society for Prenatal Diagnosis reported in 2024 that prenatal exome sequencing achieved a diagnostic yield of 31 percent for unselected pregnancies presenting with sonographically detected anomalies.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.61 Billion
Market Size 2031USD 3.89 Billion
CAGR 2026-20316.88%
Fastest Growing SegmentGenetic Diseases
Largest MarketNorth America

However, the market faces hurdles due to the high costs of advanced sequencing tests and inconsistent reimbursement landscape. Many healthcare systems and insurers limit full coverage to high-risk pregnancies, creating financial barriers that restrict the adoption of these genomic technologies among the general low-risk population. This economic friction impedes broader market expansion, preventing these advanced diagnostic tools from becoming universally accessible to all expectant parents regardless of their risk profile.

Market Driver

The market is expanding significantly due to the rapid shift toward Non-Invasive Prenatal Testing (NIPT) over traditional invasive methods, as healthcare providers and expectant parents prioritize safer, high-accuracy screening options to avoid the miscarriage risks associated with amniocentesis. This trend is evidenced by substantial growth in test volumes; for example, Natera reported in its First Quarter 2025 Financial Results that it processed approximately 855,100 tests, marking a 16.2 percent increase compared to the same period the previous year, underscoring the transition of NIPT into a mainstream standard of care.

Growth is further accelerated by technological breakthroughs in Next-Generation Sequencing (NGS) and bioinformatics, which are enabling earlier and more comprehensive fetal assessments through innovations such as single-molecule counting. Myriad Genetics noted in May 2025 that its prenatal testing revenue increased by 11 percent year-over-year, driven partly by the adoption of its Prequel Early Gestational Age test, while the sector's robust investment appeal was validated by BillionToOne's initial public offering in November 2025, which raised approximately 273 million dollars.

Market Challenge

A primary obstacle restricting the growth of the Global Prenatal DNA Sequencing Market is the prohibitive cost of advanced sequencing tests combined with uneven reimbursement policies. Despite the clinical shift toward non-invasive methods, high price points prevent these tools from becoming standard care for the low-risk population, as payers often view these evaluations as medically necessary only for high-risk pregnancies, resulting in significant out-of-pocket expenses that limit test volume and revenue potential.

The severity of these coverage gaps significantly constrains the addressable market, as illustrated by the Coalition for Access to Prenatal Screening, which reported in March 2024 that four state Medicaid programs in the United States provided zero reimbursement for non-invasive prenatal screening for any pregnant individual, regardless of risk. Such fragmented policies force genomic companies to operate within a limited market scope, directly hampering their ability to scale operations and leading to stagnated adoption rates.

Market Trends

A fundamental shift in the market is the expansion of Non-Invasive Prenatal Testing (NIPT) to encompass microdeletions and monogenic disorders, moving beyond standard aneuploidy screening to detect conditions like cystic fibrosis directly from maternal blood. This demand for comprehensive, risk-free assessment is highlighted by BillionToOne's report in January 2025, which stated that the company's revenue reached 153 million dollars in 2024, largely fueled by its single-gene prenatal testing business capturing an estimated 15 percent share of the U.S. market.

Simultaneously, the integration of third-generation long-read sequencing is revolutionizing the detection of structural variants and repeat expansions that short-read technologies often miss, offering improved diagnostic yields for pregnancies with ultrasound abnormalities. Underscoring this trend, Oxford Nanopore Technologies reported in September 2025 that revenue from its Clinical market segment increased by 52.9 percent during the first half of the year, demonstrating the rapidly growing utility of nanopore-based sequencing in clinical diagnostics.

Key Market Players

  • Agilent Technologies Inc
  • BGI Group
  • F. Hoffmann-La Roche ltd
  • Illumina Inc
  • Laboratory Corporation of America Holdings
  • Natera Inc
  • Genomic Health Inc
  • Myriad Genetics Inc
  • PerkinElmer Inc

Report Scope

In this report, the Global Prenatal DNA Sequencing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Prenatal DNA Sequencing Market, By Type

  • Genetic Diseases
  • Nonhereditary Diseases

Prenatal DNA Sequencing Market, By Application

  • Hemophilia
  • Down Syndrome
  • Cystic Fibrosis
  • Autism
  • Others

Prenatal DNA Sequencing Market, By End user

  • Hospitals And Clinics
  • Pharmaceutical And Biotechnology Companies
  • Others

Prenatal DNA Sequencing Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Prenatal DNA Sequencing Market.

Available Customizations:

Global Prenatal DNA Sequencing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Prenatal DNA Sequencing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Genetic Diseases, Nonhereditary Diseases)
    • 5.2.2. By Application (Hemophilia, Down Syndrome, Cystic Fibrosis, Autism, Others)
    • 5.2.3. By End user (Hospitals And Clinics, Pharmaceutical And Biotechnology Companies, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Prenatal DNA Sequencing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By End user
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Prenatal DNA Sequencing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End user
    • 6.3.2. Canada Prenatal DNA Sequencing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End user
    • 6.3.3. Mexico Prenatal DNA Sequencing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End user

7. Europe Prenatal DNA Sequencing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By End user
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Prenatal DNA Sequencing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End user
    • 7.3.2. France Prenatal DNA Sequencing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End user
    • 7.3.3. United Kingdom Prenatal DNA Sequencing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End user
    • 7.3.4. Italy Prenatal DNA Sequencing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End user
    • 7.3.5. Spain Prenatal DNA Sequencing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End user

8. Asia Pacific Prenatal DNA Sequencing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By End user
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Prenatal DNA Sequencing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End user
    • 8.3.2. India Prenatal DNA Sequencing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End user
    • 8.3.3. Japan Prenatal DNA Sequencing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End user
    • 8.3.4. South Korea Prenatal DNA Sequencing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End user
    • 8.3.5. Australia Prenatal DNA Sequencing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End user

9. Middle East & Africa Prenatal DNA Sequencing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By End user
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Prenatal DNA Sequencing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End user
    • 9.3.2. UAE Prenatal DNA Sequencing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End user
    • 9.3.3. South Africa Prenatal DNA Sequencing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End user

10. South America Prenatal DNA Sequencing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By End user
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Prenatal DNA Sequencing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End user
    • 10.3.2. Colombia Prenatal DNA Sequencing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End user
    • 10.3.3. Argentina Prenatal DNA Sequencing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End user

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Prenatal DNA Sequencing Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Agilent Technologies Inc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. BGI Group
  • 15.3. F. Hoffmann-La Roche ltd
  • 15.4. Illumina Inc
  • 15.5. Laboratory Corporation of America Holdings
  • 15.6. Natera Inc
  • 15.7. Genomic Health Inc
  • 15.8. Myriad Genetics Inc
  • 15.9. PerkinElmer Inc

16. Strategic Recommendations

17. About Us & Disclaimer